Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications

Cancer Research

Volumn 76, Issue 7, 2016, Pages 1882-1891

  Popova, Tatiana ^a,b   Manie, Elodie ^a,b   Boeva, Valentina ^a,b,c   Battistella, Aude ^a,b   Goundiam, Oumou ^a,b,d,e   Smith, Nicholas K ^a,b   Mueller, Christopher R ^f   Raynal, Virginie ^a,b   Mariani, Odette ^b,e   Sastre Garau, Xavier ^b,d,e   Stern, Marc Henri ^a,b  

^a INSTITUT CURIE   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c INSERM U900   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e INSTITUT CURIE   (France)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CDK12 GENE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PARAMETERS; GENOMIC INSTABILITY; HUMAN; INACTIVATING MUTATION; INDEL MUTATION; MICROHOMOLOGY END JOINING PATTERN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OVARY CANCER; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; SEQUENCE HOMOLOGY; SEROUS OVARIAN CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM DUPLICATION; TRANSCRIPTOMICS; WILD TYPE; GENETICS; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; TANDEM REPEAT;

CDK12 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE;

CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TANDEM REPEAT SEQUENCES;

EID: 84963627797     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2128     Document Type: Article

References (48)

1. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
2. Chen HH, Wang YC, Fann MJ. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol 2006;26:2736-45.
3. Blazek D, Kohoutek J, Bartholomeeusen K, Johansen E, Hulinkova P, Luo Z, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011;25:2158-72.
4. Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol 2015;35:928-38.
5. Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly (ADP-ribose) polymerase inhibitors. J Biol Chem 2014;289:9247-53.
6. Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74:287-97.
7. Cheng SW, Kuzyk MA, Moradian A, Ichu TA, Chang VC, Tien JF, et al. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol Cell Biol 2012;32:4691-704.
8. Ekumi KM, Paculova H, Lenasi T, Pospichalova V, Bosken CA, Rybarikova J, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res 2015;43:2575-89.
9. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454-62.
10. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366-75.
11. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776-82.
12. The Cancer Genome Atlas http://cancergenome.nih.gov. Accessed 20 May 2015.
13. cBioPortal for cancer genomics http://cbioportal.org/. Accessed 20 May 2015.
14. Goundiam O, Gestraud P, Popova T, De la Motte Rouge T, Fourchotte V, Gentien D, et al. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genesinnon-BRCAness high grade ovarian carcinoma. Int J Cancer 2015;137:1890-900.
15. Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, et al. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer. J Pathol 2012;226:703-12.
16. McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, etal. Tandemduplication of chromosomal segmentsiscommoninovarian and breast cancer genomes. J Pathol 2012;227:446-55.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
18. Affymetrix www.affymetrix.com. Accessed 20 May 2015.
19. Illumina www.illumina.com. Accessed 20 May 2015.
20. Popova T, Manie E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009;10:R128.
21. Homer N, Merriman B, Nelson SF. BFAST: analignment tool for large scale genome resequencing. PLoS One 2009;4:e7767.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-9.
24. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010;26:841-2.
25. Picard http://broadinstitute.github.io/picard/. Accessed 20 May 2015.
26. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011;29:24-6.
27. Zeitouni B, Boeva V, Janoueix-Lerosey I, Loeillet S, Legoix-ne P, Nicolas A, et al. SVDetect: a tool to identify genomic structural variations from pairedend and mate-pair sequencing data. Bioinformatics 2010;26:1895-6.
28. Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012;28:i333-i39.
29. Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 2012;28:423-5.
30. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19:1639-45.
31. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation ofgenetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
32. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
33. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-10.
34. Natrajan R, Wilkerson PM, Marchio C, Piscuoglio S, Ng CK, Wai P, et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014;232:553-65.
35. Robinson D, VanAllen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
36. Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014;16:475.
37. Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res 2012;72:5675-82.
38. Davidson L, Muniz L, West S. 30 end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymeraseIICTDare reciprocally coupled in human cells. Genes Dev 2014;28:342-56.
39. Ni Z, Olsen JB, Guo X, Zhong G, Ruan ED, Marcon E, et al. Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription 2011;2:237-42.
40. Ottaviani D, LeCain M, Sheer D. The role of microhomology in genomic structural variation. Trends Genet 2014;30:85-94.
41. Pannunzio NR, Li S, Watanabe G, Lieber MR. Non-homologous end joining often uses microhomology: implications for alternative end joining. DNA Repair (Amst) 2014;17:74-80.
42. Blow JJ, Gillespie PJ. Replication licensing and cancer-a fatal entanglement? Nat Rev Cancer 2008;8:799-806.
43. Llorente B, Smith CE, Symington LS. Break-induced replication: what is it and what is it for? Cell Cycle 2008;7:859-64.
44. Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 2014;343:88-91.
45. Davidson IF, Li A, Blow JJ. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol Cell 2006;24:433-43.
46. Neelsen KJ, Zanini IM, Mijic S, Herrador R, Zellweger R, Ray Chaudhuri A, et al. Deregulated origin licensing leads to chromosomal breaks by rereplication of a gapped DNA template. Genes Dev 2013;27:2537-42.
47. Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol Cell 2015;57:636-47.
48. Bartkowiak B, Yan C, Greenleaf AL. Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas. Biochim Biophys Acta 2015;1849:1179-87.